The Pharmaceutical Research and Manufacturers of America (PhRMA) issued the following statement on recommendations voted on at the April meeting of the Medicare Payment Advisory Commission (MedPAC): “PhRMA strongly opposes the sweeping new Medicare Part D recommendations approved by MedPAC earlier today.